Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

sus temsirolimus in relapsed or refractory  MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a mono-therapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression free survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in subjects with newly diagnosed MCL. The primary endpoint of the study is progression free survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen, is open and Janssen plans to enroll 110 patients worldwide.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... (MIPT and Russian Quantum Center at Skolkovo) and ... and the Institute of Physics in Bratislava, Slovakia) ... of particles passing through an amplifier and, conversely, ... are provided in an article published in the ... , Quantum entangled particles are considered to be ...
    (Date:7/23/2014)... 2014 Last year, Formedix ... leading global provider of data management solutions for clinical ... leading-edge system for electronic data capture (EDC) and clinical ... and study execution tools added TrialMaster to its Transform ... version of Transform for TrialMaster, is being released this ...
    (Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
    (Date:7/23/2014)... , July 23, 2014  Sofinnova Ventures, a ... announced the closing of Sofinnova Venture Partners IX, L.P. ... excess of the initial fund target of $425 million. ... successful biotechnology companies. Consistent with recent funds, SVP IX ... stage clinical programs, along with select investments in earlier ...
    Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
    ... WOBURN, Mass., April 7, 2011 The Center for Business ... to the American Red Cross in support of the relief ... employees made personal contributions to the fund while the organization ... the compassion and generosity CBI employees have displayed to help ...
    ... Fla. April 5, 2011 A new drug is ... an inherited predisposition to the disease. These patients with ... which can become locally invasive or metastatic, according to a ... at the 102nd annual meeting of the American Association for ...
    ... (Nasdaq: CEPH ) has scheduled its regular quarterly ... p.m. EDT on Tuesday, May 3, 2011. May 3, ... be distributed by PRNewswire4:50 p.m. EDT , To participate in ... 67208985:00 p.m. EDT , Conference call begins promptly. Simultaneous ...
    Cached Biology Technology:The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan 2New drug is effective against the most common form of skin cancer 2
    (Date:7/23/2014)... NY -- The potential for clinical use of ... therapeutic strategies has previously been hindered by the ... of tumors. The ability to use etoposide treatment ... treatment of heart disease, specifically acute myocardial infarction, ... Cells and Development , a peer-reviewed journal from ...
    (Date:7/23/2014)... WELLESLEY, Massachusetts , July 23, 2014 ... reveals in its new report, GLOBAL MARKETS AND ... and related technologies is expected to grow to nearly ... growth rate (CAGR) of 10.1%. The image, flow, and ... CAGR.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
    (Date:7/23/2014)... This news release is available in German . ... use varying sensory modalities for orientation, some of which ... for example take the polarization pattern produced by sunlight ... researchers from the Max Planck Institute for Ornithology in ... colleagues from Israel that a night active mammal, the ...
    Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3Bats use the evening sky's polarization pattern for orientation 2
    ... Building Components (UHGBC), a program in the Gerald D. ... Expo. This event showcases the work of faculty-led research ... and sustainable technologies for the built environment. The ... the College of Architecture,s atrium. The event is free ...
    ... If Guinness World Records had a category for the largest ... just claimed it. They have designed and successfully ... manufacture the essential amino acid histidine. It is more than ... created by researchers at the University of Washington in 2003. ...
    ... study conducted by researchers at the Johns Hopkins Malaria ... of drug resistance in malaria-causing parasites taken from both ... human blood samples showed a high prevalence for pyrimethamine-resistance, ... used to treat malaria in the region. However, parasites ...
    Cached Biology News:UH Green Building Components Expo showcasing eco-friendly projects 2Creation of the largest human-designed protein boosts protein engineering efforts 2Creation of the largest human-designed protein boosts protein engineering efforts 3Contrasting patterns of malaria drug resistance found between humans and mosquitoes 2
    Request Info...
    ... blotted protein on PVDF membrane or with ... N-terminal sequence of proteins (5-20 residues) can ... HPLC or mono-and bidimensional SDS-PAGE, followed by ... the well known EDMAN degradation method. Pre-treatment ...
    Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
    ELF® 97 Immunohistochemistry Kit...
    Biology Products: